RxDoctor Payments Data

Salvador Peron, MD

Urology · Toledo, OHNPI 1881691640

Payments from drug & device makers

$14,126in general payments, 2019–2025

Across 300 payments — averaging $47.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$4K
  • Boston Scientific$2K
  • Axonics, Inc.$2K
  • Astellas Pharma US Inc$1K
  • Medtronic$1K
  • Johnson & Johnson$613
  • plus $4K from 38 others

What the payments were for

  • Speaking & faculty fees$4733%
  • Travel & lodging$5,40638%
  • Food & beverage$7,70055%
  • Education$5484%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,126 in reported general payments places this provider in the 80th percentile of 485 urology providers in Ohio.

See all urology providers in Ohio

Medicare billing

Part B allowed, 2024
$227,497
Medicare patients
460
Services billed
1,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix28$76,334
MyrbetriqMirabegron88$62,902
GemtesaVibegron41$39,064
Dutasteride580$20,104
Tamsulosin Hcl921$12,444
Mirabegron ErMirabegron11$11,038
Silodosin114$9,349
Finasteride384$4,217
Solifenacin Succinate89$3,818
Potassium Citrate ErPotassium Citrate19$3,540
Trospium Chloride114$2,932
Tolterodine Tartrate ErTolterodine Tartrate38$2,818
Oxybutynin Chloride ErOxybutynin Chloride83$2,234
Gentamicin Sulfate20$1,721
Methenamine Hippurate25$1,490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$218$115,39969 claims
Astellas Pharma US IncMyrbetriq$1,089$62,90288 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 485 urology providers in Ohio.

Other urology in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →